CARGO Therapeutics, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q2 2025.
-
Location
-
San Carlos, CA
-
Fiscal year end
-
31 December
-
Latest financial report
-
06 Aug 2025
Quick Takeaways
- CARGO Therapeutics, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q2 2025.
- Headline metric: Return On Equity -66%.
What Changed
- Return On Equity YoY change: <span class="text-red-600">-20%</span>.
- Most recent SEC facts end date: 01 Aug 2025.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2025-08-01) highlights Return On Equity -65.8%, Return On Assets -59.2%, and Current Ratio 12.37x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
21.0/100
Weak
Confidence medium
Return On Equity
-66%
Metric score 0.0/100
Return On Assets
-59%
Metric score 0.0/100
Financial Health
- Current Ratio
- 12.37x
- Debt to Equity
- 0.16x
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Key metrics snapshot
Return On Equity
-66%
YoY: -20%
Industry median:
-47%
(n=218)
View history
Return On Assets
-59%
YoY: +97%
Industry median:
-44%
(n=217)
View history
Current Ratio
12.37x
YoY: -27%
Industry median:
3.67x
(n=218)
View history
Debt-to-equity
0.16x
YoY: -8.4%
Industry median:
0.31x
(n=169)
View history
NetIncomeLoss YoY
-50%
YoY:
Industry median:
-12%
(n=211)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
-66%
|
-20%
|
-47%
(n=218)
|
Q2 2025
|
Q2 2025
|
%
|
|
Return On Assets
|
-59%
|
+97%
|
-44%
(n=217)
|
Q2 2025
|
Q2 2025
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
12.37x
|
-27%
|
3.67x
(n=218)
|
Q2 2025
|
Q2 2025
|
x
|
|
Debt-to-equity
|
0.16x
|
-8.4%
|
0.31x
(n=169)
|
Q2 2025
|
Q2 2025
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
NetIncomeLoss YoY
|
-50%
|
|
-12%
(n=211)
|
Q2 2025
|
Q2 2025
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
48,364,311
|
+5.4%
|
Q2 2025
|
Q2 2025
|
shares
|
|
Common Stock, Value, Issued
|
$46,000
|
0%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
48,133,609
|
+11%
|
Q2 2025
|
Q2 2025
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
48,133,609
|
+11%
|
Q2 2025
|
Q2 2025
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Research and Development Expense
|
$113,582,000
|
-3.1%
|
Q2 2025
|
Q2 2025
|
USD
|
|
General and Administrative Expense
|
$41,610,000
|
+14%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Operating Income (Loss)
|
$238,570,000
|
-55%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Earnings Per Share, Basic
|
-4
|
-116%
|
Q2 2025
|
Q2 2025
|
USD/shares
|
|
Earnings Per Share, Diluted
|
-4
|
-116%
|
Q2 2025
|
Q2 2025
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$107,746,000
|
-30%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Marketable Securities, Current
|
$144,821,000
|
-50%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Assets, Current
|
$258,605,000
|
-42%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Assets
|
$258,605,000
|
-47%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Accounts Payable, Current
|
$8,668,000
|
+24%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Employee-related Liabilities, Current
|
$25,000
|
-99%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Accrued Liabilities, Current
|
$739,000
|
-87%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Liabilities, Current
|
$20,908,000
|
-21%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Operating Lease, Liability, Noncurrent
|
$0
|
-100%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Liabilities
|
$20,908,000
|
-61%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$9,000
|
+97%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$447,083,000
|
-98%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$237,697,000
|
-45%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Liabilities and Equity
|
$258,605,000
|
-47%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$108,313,000
|
-30%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Operating Lease, Liability
|
$578,000
|
-98%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Depreciation
|
$2,216,000
|
+4%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$221,464,000
|
-50%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Lessee, Operating Lease, Liability, to be Paid
|
$584,000
|
-99%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Operating Lease, Liability, Current
|
$578,000
|
-11%
|
Q2 2025
|
Q2 2025
|
USD
|
|
Operating Lease, Weighted Average Discount Rate, Percent
|
0.13
|
-7.3%
|
Q2 2025
|
Q2 2025
|
pure
|
|
Additional Paid in Capital
|
$684,743,000
|
+3.5%
|
Q2 2025
|
Q2 2025
|
USD
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets